Moderna (WBO:MRNA) EBITDA Margin % : 9.88% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Moderna EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Moderna's EBITDA for the three months ended in Dec. 2023 was €255 Mil. Moderna's Revenue for the three months ended in Dec. 2023 was €2,580 Mil. Therefore, Moderna's EBITDA margin for the quarter that ended in Dec. 2023 was 9.88%.

Moderna EBITDA Margin % Historical Data

The historical data trend for Moderna's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna EBITDA Margin % Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

-1,072.92

-267.15

76.27

52.73

-48.61

Moderna Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial															33.89	-11.86	-520.25	-95.08	9.88

Competitive Comparison of Moderna's EBITDA Margin %

For the Biotechnology subindustry, Moderna's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Moderna's EBITDA Margin % falls into.

Moderna EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Moderna's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-3010.511	/	6193.418
	=	-48.61 %

Moderna's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	254.926	/	2579.521
	=	9.88 %

Moderna (WBO:MRNA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Moderna EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Moderna's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna (WBO:MRNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (WBO:MRNA) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0A45:UK 0QF:Germany M1RN34:Brazil

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.